Research programme: Pan-HER inhibitors - SUGEN/Baxter Oncology

Drug Profile

Research programme: Pan-HER inhibitors - SUGEN/Baxter Oncology

Alternative Names: D-69491; SU 11464

Latest Information Update: 11 Dec 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ASTA Medica [CEASED]; SUGEN
  • Developer Baxter Oncology; SUGEN
  • Class Small molecules
  • Mechanism of Action Epidermal growth factor inhibitors; ERBB 2 receptor antagonists; ERBB 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 11 Dec 2002 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 06 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation
  • 21 Sep 1999 SUGEN has been acquired by Pharmacia & Upjohn
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top